Enhance myogenic transdifferentiation efficiency using engineering approaches
Enhance myogenic transdifferentiation efficiency using engineering approaches
批准号:
10647491
负责人:
Wei Shen
金额:
$19.66万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-05-01 至 2025-04-30
关键词:
AgingBiologicalCell modelCellsChromatinDiseaseDisease modelEngineeringEnhancersEpigenetic ProcessExhibitsFutureGenesGenetic TranscriptionGoalsHeterogeneityHumanMicroRNAsModelingMolecularMuscleMuscle CellsMuscle FibersMyopathyNaturePathway interactionsPatientsPatternPhenotypePhysiologicalProcessReproducibilityRiskSomatic CellSurfaceTechnologyTeratomaTestingTherapeuticcostdifferential expressiondirect applicationgenome-wide analysishigh throughput screeningimprovedmatrigelnew technologynovelrational designthree dimensional cell culturetranscription factortransdifferentiation
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Myogenic direct reprogramming from non-muscle somatic cells has become an important strategy to
produce abundant, patient-specific, and disease-specific human myogenic cells, which are highly desirable for
therapeutic applications and disease modeling. As compared to deriving myogenic cells from hiPSCs, direct
reprogramming is substantially quicker, and reprogrammed cells avoid the risk of teratoma formation and retain
aging- and disease-associated epigenetic signatures, which is particularly important for modeling aging-related
muscle diseases. Despite these advantages, applications of directly reprogrammed myogenic cells are
hampered by low reprogramming efficiency and their immature nature. It is challenging to improve
reprogramming through rational design, as molecular mechanisms underlying the process remain largely
unknown; therefore, high-throughput screening (HTS) is an important strategy to expedite discovery of more
efficient direct reprogramming technologies. A major hurdle to effective HTS for direct reprogramming
technologies is the difficulty to establish a simple, low-cost phenotypic readout that truly represents an integrative
biological endpoint defining the target lineage. We recently discovered that myogenic cells cultured on surfaces
patterned with parallel nanogrooves/ridges and functionalized with Matrigel form myotubes aligning nearly
perpendicular to the nanogrooves, and this phenotype is unique and universal for all non-diseased myogenic
cells, regardless of their origin and species. Quantitative analysis of myotube orientations reveals a single peak
near 90°; furthermore, when normal myogenic cells are mixed with diseased cells that do not exhibit this
phenotype, myotube orientation angle decreases with the percentage of the normal myogenic cells. We
hypothesize that when cultured on nanogrooved, Matrigel-functionalized surface, myotubes derived from
reprogrammed cells will exhibit increased orientation angles relative to the nanogrooves with increasing
reprogramming efficiency, and this highly reproducible and quantifiable phenotype will provide a simple, low-
cost, and physiologically relevant readout for effective HTS to discover efficient myogenic reprogramming
technologies. We plan to test our hypothesis by (1) developing a high-throughput screening platform using
myotube orientation relative to nanogrooves as a physiologically relevant readout and use this platform to
discover novel small compounds capable of enhancing myogenic reprogramming efficiency, (2) characterizing
the myotubes at molecular, structural, and functional levels, and (3) dissecting transcriptional and epigenetic
mechanisms underlying the positive effects of the novel compounds. The proposed study will result in new
technologies to generate directly reprogrammed human myogenic cells exhibiting more similarities to true
myogenic cells. The established HTS platform can be used to discover other types of enhancers for myogenic
reprogramming (transcription factors, microRNAs) and the enriched pathways and motifs identified in the cells
reprogrammed with the novel compounds will indicate novel targets to further improve reprogramming efficiency.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Nanoscale Assembly of Bioactive Ligands to Enhance Endothelial Differentiation
-
批准号:8241196
-
项目类别:
-
资助金额:$18.09万
-
财政年份:2012
-
负责人:Wei Shen
-
依托单位:
Nanoscale Assembly of Bioactive Ligands to Enhance Endothelial Differentiation
-
批准号:8410532
-
项目类别:
-
资助金额:$20.82万
-
财政年份:2012
-
负责人:Wei Shen
-
依托单位:
Modular Assembly Approach to Engineer Prevascularized Large 3D Tissue Constructs
-
批准号:8138172
-
项目类别:
-
资助金额:$18.16万
-
财政年份:2011
-
负责人:Wei Shen
-
依托单位:
Modular Assembly Approach to Engineer Prevascularized Large 3D Tissue Constructs
-
批准号:8321540
-
项目类别:
-
资助金额:$21.93万
-
财政年份:2011
-
负责人:Wei Shen
-
依托单位:
海外基金